Published in Drug Week, February 10th, 2006
This second phase III clinical study was a randomized, double blind, vehicle-controlled study evaluating the safety and efficacy of AzaSite in patients with bacterial conjunctivitis. The randomized patients were treated for 5 days, twice daily for the first 2 days followed by once per day for days 3-5, with either AzaSite or a vehicle formulation. The goal of the study is to demonstrate superiority of AzaSite as...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.